Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic

Vividion Therapeutics, a biotechnology company that launched in 2017 around discoveries made in Scripps Research Institute labs, has raised $82 million in financing. Nextech Invest, a Swiss investment firm that funds companies developing cancer therapeutics, led the Series B round of funding. As part of the investment, Nextech partner Jakob Loven gets a board seat. [?]